Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2008

01-01-2008 | Original Paper

Angiotensin II Type 1 Receptor Expression in Human Gastric Cancer and Induces MMP2 and MMP9 Expression in MKN-28 Cells

Authors: Wei Huang, Li-Fen Yu, Jie Zhong, Min-Min Qiao, Feng-Xiang Jiang, Fang Du, Xiang-Long Tian, Yun-Lin Wu

Published in: Digestive Diseases and Sciences | Issue 1/2008

Login to get access

Abstract

Angiotensin II (Ang II), a main effector peptide in the renin–angiotensin system, acts as a growth-promoting and angiogenic factor via angiotensin II receptor1 (AT1R). In this study, we investigated the expression of angiotensin II type1 receptor (AT1R) in gastric cancer and the effects of Ang II on the expression of MMP2 and MMP9 in the human gastric cancer cell line MKN-28 cells. The expression of the Ang II type I receptor was examined by western and immunocytochemistry in gastric cancer cell lines and detected by real-time PCR and immunohistochemistry in normal and gastric cancer tissues. The expression of MMP2 and MMP9 were detected by real-time PCR and western after treatment with Ang II and/or AT1R antagonist. AT1R were expressed in all human gastric cancer lines and the expression of AT1R was significantly higher in cancer tissues than that in normal gastric tissues (P < 0.01). Furthermore, Ang II promoted the expression of MMP2 and MMP9 in MKN-28 cells, and the stimulatory effects of Ang II could be blocked by AT1R antagonist. These results suggest that AT1R is involved in the progression of gastric cancer and may promote the angiogenesis of gastric cancer cell line (MKN-28), and these effects may be associated with the upregulation of MMP2 and MMP9.
Literature
1.
Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16(7):293–299PubMedCrossRef
2.
Ino K, Shibata K, Kajiyama H et al (2006) Manipulating the angiotensin system – new approaches to the treatment of solid tumours. Expert Opin Biol Ther 6(3):243–255PubMedCrossRef
3.
Escobar E, Rodriguez-Reyna TS, Arrieta O et al (2004) Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2(4):385–399PubMedCrossRef
4.
Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRef
5.
Parsons SL, Watson SA, Collins HM et al (1998) Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78(11):1495–1502PubMed
6.
Wang M, Zhang J, Spinetti G et al (2005) Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 167(5):1429–1442PubMed
7.
Sawicki G, Menon V, Jugdutt B (2004) Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 10(5):442–449PubMedCrossRef
8.
Williams RN, Parsons SL, Morris TM et al (2005) Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 31(9):1042–1050PubMedCrossRef
9.
Dinh DT, Frauman AG, Somers GR et al (2002) Evidence for activation of the renin–angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 196(2):213–219PubMedCrossRef
10.
Lam KY, Leung PS (2002) Regulation and expression of a renin–angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol 146(4):567–572PubMedCrossRef
11.
De Paepe B, Verstraeten VL, De Potter CR et al (2001) Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 116(3):247–254PubMed
12.
Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158(5):1633–1637PubMed
13.
Fujimoto Y, Sasaki T, Tsuchida A et al (2001) Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495(3):197–200PubMedCrossRef
14.
Ino K, Shibata K, Kajiyama H et al (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 94(4):552–560PubMedCrossRef
15.
Kikkawa F, Mizuno M, Shibata K et al (2004) Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 190(5):1258–1263PubMedCrossRef
16.
Prontera C, Mariani B, Rossi C et al (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81(5):761–766PubMedCrossRef
17.
Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62(15):4176–4179PubMed
18.
Kondo K, Muramatsu M, Okamoto Y et al (2006) Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93(1):36–42PubMedCrossRef
Metadata
Title
Angiotensin II Type 1 Receptor Expression in Human Gastric Cancer and Induces MMP2 and MMP9 Expression in MKN-28 Cells
Authors
Wei Huang
Li-Fen Yu
Jie Zhong
Min-Min Qiao
Feng-Xiang Jiang
Fang Du
Xiang-Long Tian
Yun-Lin Wu
Publication date
01-01-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9838-9

Other articles of this Issue 1/2008

Digestive Diseases and Sciences 1/2008 Go to the issue

Original Paper

Twenty-Four Hour Tonometry in Patients Suspected of Chronic Gastrointestinal Ischemia

Original Paper

The Benefit of the Supplementation of Perioperative Branched-Chain Amino Acids in Patients with Surgical Management for Hepatocellular Carcinoma: a Preliminary Study

OriginalPaper

Pneumatosis Intestinalis and Portal Venous Gas Without Bowel Ischemia in a Patient Treated with Irinotecan and Cisplatin

Original Paper

Modulation of Rat Intestinal Nuclear Factor NF-κB by Gum Arabic

OriginalPaper

False-positive Findings for Tumor Markers after Curative Gastrectomy for Gastric Cancer

Original Paper

Development of Functional Diarrhea, Constipation, Irritable Bowel Syndrome, and Dyspepsia During and After Traveling Outside the USA
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits